SALV.L

SalvaRx Group Plc
SalvaRx Group plc - Transaction Update
21st November 2018, 13:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1025I
SalvaRx Group plc
21 November 2018
 

SalvaRx Group plc

("SalvaRx", the "Company" or the "Group")

Transaction Update

 

Further to the announcements of 14 and 28 August 2018 relating to the proposed disposal of the Company's 94.2% interest in SalvaRx Limited to Portage Biotech Inc. ("Portage"), the Company is pleased to announce that the Portage shareholder meeting to approve the transaction has been set for 8 January 2019 and meeting materials will be sent to Portage shareholders on the Portage record date, being 23 November 2018.  Trading in Portage shares on the Canadian Securities Exchange is expected to resume shortly after the meeting materials have been posted.

 

The Company will now finalise and publish its shareholder circular and a further announcement will be made by the Company in due course.

 

Enquiries

SalvaRx Group plc

 

Ian Walters (Chief Executive)

Tel: +1 203-441-5451

Northland Capital Partners Limited

Nominated Adviser and Broker

Tel: +44 (0) 20 3861 6625

 

Matthew Johnson / Edward Hutton (Corporate Finance)


Vadim Alexandre (Corporate Broking)


Peterhouse Capital Limited

Joint Broker

Lucy Williams / Duncan Vasey

Tel: +44 (0) 20 7469 0932

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DISPGGGAGUPRGPG ]]>
TwitterFacebookLinkedIn